*  Richard Cathomas, Chur, comments on the urogenital Carcinoma Highlights - Oncoletter, Webportal für Onkologie und onkologische...
... failure free survival HR = 0.51 (0.39-0.67); progression free survival HR 0.65 (0.48-0.88); metastases free survival HR 0.77 ( ... Revolutionizing Sickle Cell Disease Care in the United States and Abroad. *Improved Outcomes in Leukemia, Trauma Settings with ... Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) mCRC patients treated with FOLFIRI plus cetuximab in the CAPRI- ... Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) mCRC patients treated with FOLFIRI plus cetuximab in the CAPRI- ...
  https://www.oncoletter.ch/esmo-2017/richard-cathomas-urogenital-carcinoma.html
*  Health and Medical Sources
To somewhat increase the likelihood of long-term disease-free survival, several chemotherapy regimens are commonly given in ... in England that are diagnosed with the disease survive it for at least 5 years. In the developing countries, however, survival ... Survival rates in the Western World are very good, for instance, overall, more than 8 out of 10 women (84%) ... Prognosis and survival rates vary greatly depending on cancer type, staging and treatment, and geographical location of the ...
  http://healthandmedicalsources.com/?action=breast
*  New Data Evaluating the Safety and Preliminary Relapse-Free Survival of Adjuvant Yervoy (ipilimumab) 3 mg/kg and 10 mg/kg in...
New Data Evaluating the Safety and Preliminary Relapse-Free Survival of Adjuvant Yervoy (ipilimumab) 3 mg/kg and 10 mg/kg in ... Permanently discontinue YERVOY for immune-mediated ocular disease unresponsive to local immunosuppressive therapy. In Trial 1, ... Relapse-free survival at three years was 56% for Yervoy 3 mg/kg and 54% for Yervoy 10 mg/kg ... New Data Evaluating the Safety and Preliminary Relapse-Free Survival of Adjuvant Yervoy (ipilimumab) 3 mg/kg and 10 mg/kg in ...
  https://www.businesswire.com/news/home/20170604005028/en/New%C2%A0Data-Evaluating%C2%A0the-Safety-Preliminary-Relapse-Free-Survival-Adjuvant
*  a) Overall survival (OS) and (b) progression-free surv | Open-i
... progression-free survival (PFS) assessed by Kaplan-Meier methodology in the overall population of patients with unresectable ... Bottom Line: Interstitial lung disease was confirmed in 429 (4.3%) patients.These data confirm the well-characterized safety ... fig03: (a) Overall survival (OS) and (b) progression-free survival (PFS) assessed by Kaplan-Meier methodology in the overall ... fig03: (a) Overall survival (OS) and (b) progression-free survival (PFS) assessed by Kaplan-Meier methodology in the overall ...
  https://openi.nlm.nih.gov/detailedresult.php?img=PMC4317960_cas0105-1584-f3&req=4
*  Penny PayDay: Galena Bio (Nasdaq: GALE) NeuVax Phase 1/2 boosters improve disease-free survival at 60 month
The results show that, at a median of 60-months, the disease-free survival (DFS) for the booster group (n=53) was 96.2% vs 80.5 ... Galena Bio (Nasdaq: GALE) NeuVax Phase 1/2 boosters improve disease-free survival at 60 month ...
  http://penny-payday.blogspot.com/2012/06/galena-bio-nasdaq-gale-neuvax-phase-12.html
*  Disease-free survival curve (A) and overall survival cu | Open-i
... and overall survival curve (B) according to CD44s protein expression. CD44s expression correlates with a negative prognosis (A ... Figure 2: Disease-free survival curve (A) and overall survival curve (B) according to CD44s protein expression. CD44s ... Figure 2: Disease-free survival curve (A) and overall survival curve (B) according to CD44s protein expression. CD44s ... Conclusions: High CD44s protein expression correlates with shorter disease free survival and poorly differentiated HCC. CD44s- ...
  https://openi.nlm.nih.gov/detailedresult.php?img=PMC3140667_gnl-5-204-g002&req=4
*  Prolonged Progression-Free Survival Reinforces Tucatinib's Potential for Patients with Advanced HER2+ Metastatic Breast Cancer ...
... today announced that tucatinib in combination with standard of care agents demonstrated prolonged progression-free survival ( ... HER2 disease has been associated with shorter survival times as well as a higher risk of recurrence and CNS disease (brain ... Home Entertainment Prolonged Progression-Free Survival Reinforces Tucatinib's Potential for Patients with Advanced HER2+ ... Prolonged Progression-Free Survival Reinforces Tucatinib's Potential for Patients with Advanced HER2+ Metastatic Breast Cancer ...
  https://culthub.com/entertainment/prolonged-progression-free-survival-reinforces-tucatinibs-potential-for-patients-with-advanced-her2-metastatic-breast-cancer/39449
*  Vaccine Increases Disease-Free Survival for Follicular Lymphoma Patients | MD Anderson Cancer Center
Vaccine Increases Disease-Free Survival for Follicular Lymphoma Patients. MD Anderson News Release 05/31/2011 ... A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better ... extending disease-free survival time from 28.7 months to 52.9 months. While those results need to be confirmed in randomized ... "Survival of follicular lymphoma patients has improved with newer types of chemotherapy, but advanced-stage disease still is ...
  https://www.mdanderson.org/newsroom/2011/05/vaccine-increases-disease-free-survival-for-follicular-lymphoma-.html
*  Survival and disease-free survival by breast density and phenotype in interval breast cancers | Cancer Epidemiology, Biomarkers...
Survival and disease-free survival by breast density and phenotype in interval breast cancers. Maria Sala, Laia Domingo, Javier ... Survival and disease-free survival by breast density and phenotype in interval breast cancers ... Background:We aimed to evaluate survival and disease-free survival in different subtypes of interval cancers by breast density ... Survival and disease-free survival by breast density and phenotype in interval breast cancers ...
  http://cebp.aacrjournals.org/content/early/2018/05/31/1055-9965.EPI-17-0995
*  Neratinib Improves Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer - The ASCO Post
Neratinib Improves Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer. By Chase Doyle and Caroline Helwick. ... "ExteNET is the first study to show a statistically significant improvement in invasive disease-free survival in the intent-to- ... ExteNet's primary analysis was the invasive disease-free survival for all patients treated who had completed 2 years of follow- ... 2. Chan A, Martin M, Von Minckwitz G, et al: Invasive disease-free survival benefit following neratinib as extended adjuvant ...
  http://www.ascopost.com/issues/november-25-2015/neratinib-improves-disease-free-survival-in-early-stage-her2-positive-breast-cancer/
*  Smoking Linked to Shorter Disease-free Survival in Stage III Colon Cancer - The ASCO Post
... with significantly poorer disease-free survival observed for current vs never-smokers with BRAF wild-type disease (HR = 1.60, ... there was evidence of poorer disease-free survival for smokers vs nonsmokers with KRAS mutant disease. Among patients with KRAS ... Disease-free Survival in Ever-smokers. Median follow up in patients not experiencing events was 3.5 years. On unadjusted ... However, disease-free survival was significantly poorer for ever-smokers vs never-smokers who were male (HR = 1.33, 95% CI = ...
  http://www.ascopost.com/issues/june-10-2013/smoking-linked-to-shorter-disease-free-survival-in-stage-iii-colon-cancer/
*  Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem...
S. G. Holtan, T. E. DeFor, A. Lazaryan et al., "Composite end point of graft-versus-host disease-free, relapse-free survival ... Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem ... A. Jalali, K. Alimoghaddam, M. Mahmoudi et al., "The EBMT risk score in the presence of graft versus host disease in allogeneic ... P. Ljungman, M. Hakki, and M. Boeckh, "Cytomegalovirus in hematopoietic stem cell transplant recipients," Infectious Disease ...
  https://www.hindawi.com/journals/sci/2016/5143071/ref/
*  Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing...
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast ... Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing ... to these patients may result in the elimination of HER2 expressing disseminated tumor cells and improved disease free survival. ... Breast Diseases. Skin Diseases. Paclitaxel. Docetaxel. Liposomal doxorubicin. Albumin-Bound Paclitaxel. Cyclophosphamide. ...
  https://clinicaltrials.gov/ct2/show/NCT01779050
*  Renal-Cell Cancer Disease-Free Survival Up With Sunitinib | Physician's Weekly for Medical News, Journals & Articles
Renal-Cell Cancer Disease-Free Survival Up With Sunitinib by Logan Thomison , Oct 11, 2016 , 0 comments ... The researchers found that the median duration of disease-free survival was 6.8 and 5.6 years in the sunitinib and placebo ... 11, 2016 (HealthDay News) - The duration of disease-free survival is increased with sunitinib treatment for patients with ... the median duration of disease-free survival was significantly longer in the sunitinib group than in the placebo group, at a ...
  https://www.physiciansweekly.com/renal-cell-cancer-disease-free-survival-up-with-sunitinib/
*  Disease-free survival was estimated using the Kaplan-Me | Open-i
Disease-free survival was estimated using the Kaplan-Meier method anddefined as the period between diagnosis and local or ... f01: Disease-free survival was estimated using the Kaplan-Meier method anddefined as the period between diagnosis and local or ... f01: Disease-free survival was estimated using the Kaplan-Meier method anddefined as the period between diagnosis and local or ... and its association with prognostic factors and disease-free survival. Martins DM, Vidal FC, Souza RD, Brusaca SA, Brito LM - ...
  https://openi.nlm.nih.gov/detailedresult.php?img=PMC4230293_1414-431X-bjmbr-47-11-01008-gf001&req=4
*  Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma | Clinical...
Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma. Ernest Nadal ... Patients with increased miR-34b/c methylation had significantly shorter disease-free and overall survival as compared to ... Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma ... Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma ...
  http://clincancerres.aacrjournals.org/content/early/2013/12/12/1078-0432.CCR-13-0736
*  Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897...
... and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer. Song Yao, William E. Barlow, Kathy S. Albain, Ji-Yeob ... Adjuvant chemotherapy for early stage breast cancer patients has greatly improved both disease-free and overall survival by ... Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest ... Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial ...
  http://clincancerres.aacrjournals.org/content/16/24/6169.long
*  Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free...
... and reduced disease-free survival (P , 0.05).. Conclusions: IGF2 modulates Taxol resistance, and tumor IGF2 expression is a ... Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian ... Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian ... Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian ...
  http://clincancerres.aacrjournals.org/content/early/2010/05/13/1078-0432.CCR-09-3233
*  A) Disease-free survival and overall survival for pati | Open-i
A) Disease-free survival and overall survival for patients undergoing total laparoscopic radical hysterectomy (TLRH) or ... Figure 2: (A) Disease-free survival and overall survival for patients undergoing total laparoscopic radical hysterectomy (TLRH ... Figure 2: (A) Disease-free survival and overall survival for patients undergoing total laparoscopic radical hysterectomy (TLRH ... Disease-free survival and overall survival for patients with early-stage cervical cancer undergoing TLRH or ARH, and with ...
  https://openi.nlm.nih.gov/detailedresult.php?img=PMC4554128_medi-94-e1264-g005&req=4
*  No Disease-Free Survival Benefit of Adjuvant Sunitinib or Sorafenib in High-Risk Nonmetastatic Renal Cell Carcinoma - The ASCO...
No Disease-Free Survival Benefit of Adjuvant Sunitinib or Sorafenib in High-Risk Nonmetastatic Renal Cell Carcinoma. By Matthew ... Disease-Free Survival Due to low conditional power for the primary endpoint, the Data Safety Monitoring Committee recommended ... Five-year disease-free survival was 54.3%, 54.0%, and 56.4%, respectively.. Among patients with clear cell histology ( ... The primary objective was to compare disease-free survival between each experimental group and placebo in the intention-to- ...
  http://www.ascopost.com/issues/may-25-2016/no-disease-free-survival-benefit-of-adjuvant-sunitinib-or-sorafenib-in-high-risk-nonmetastatic-renal-cell-carcinoma/
*  Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival | Breast Cancer Research | Full Text
Postoperative radiotherapyPreoperative radiotherapyEarly-stage breast cancerOverall survivalDisease-free survivalImmune ... Neoadjuvant RT may significantly improve disease-free survival without reducing overall survival, especially for estrogen ... improves relapse-free survival of patients with early-stage breast cancer. We evaluated the long-term overall and disease-free ... Disease-free survival, defined as time to diagnosis of a second primary tumor at any location, was calculated from automated ...
  https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-017-0870-1
*  Tumor Diameter for Prediction of Recurrence, Disease Free and Overall Survival in Endometrial Cancer Cases | Korea Science
Disease Free and Overall Survival in Endometrial Cancer Cases - Endometrial cancer;tumor diameter;overall survival;disease free ... Aims: To analyse the predictors of recurrence, disease free survival and overall survival in cases with endometrial cancer. ... disease free survival and overall survival. Results: In ROC analyses tumor diameter was a significant predictor of recurrence ( ... Tumor Diameter for Prediction of Recurrence, Disease Free and Overall Survival in Endometrial Cancer Cases. Senol, Taylan; ...
  http://www.koreascience.or.kr/article/ArticleFullRecord.jsp?cn=POCPA9_2015_v16n17_7463
*  The relationship of high neutrophil-to-lymphocyte ratio to disease-free survival in colorectal cancer | OncologyPRO
The relationship of high neutrophil-to-lymphocyte ratio to disease-free survival in colorectal cancer. ... The relationship of high neutrophil-to-lymphocyte ratio to disease-free survival in colorectal cancer ... ESMO Consensus Conferences discuss key questions in certain disease areas and complement the ESMO Clinical Practice Guidelines ...
  https://oncologypro.esmo.org/Meeting-Resources/World-GI-2016/The-relationship-of-high-neutrophil-to-lymphocyte-ratio-to-disease-free-survival-in-colorectal-cancer
*  Zoledronic Acid Did Not Improve Disease Free Survival in Early Breast Cancer | AACR News
Zoledronic acid did not improve disease free survival among women with stage II/III breast cancer according to results of the ... The primary outcome was disease free survival.. The researchers found no difference in disease free survival in the overall ... SAN ANTONIO - Zoledronic acid did not improve disease free survival among women with stage II/III breast cancer according to ... Zoledronic Acid Did Not Improve Disease Free Survival in Early Breast Cancer. December 9, 2010 ...
  https://aacrnews.wordpress.com/2010/12/09/zoledronic-acid-did-not-improve-disease-free-survival-in-early-breast-cancer/
*  Organ Preservation in Rectal Adenocarcinoma: A phase II randomized controlled trial evaluating 3-year disease-free survival in...
Organ Preservation in Rectal Adenocarcinoma: A phase II randomized controlled trial evaluating 3-year disease-free survival in ...
  http://vivo.med.cornell.edu/display/pubid84944907528